Does ezetimibe modify clinical outcomes?
Only the IMPROVE-IT trial provides meaningful data on ezetimibe. In acute coronary syndrome patients^ adding ezetimibe to moderate-intensity statin prevents one cardiovascular event for every 50 people treated for seven years. Baseline LDL level did not influence this benefit. There are no data for ezetimibe in primary prevention^ but the benefit is likely proportional to (lower) baseline CVD risk.
*** Original Documents can be found and downloaded using the link provided below ***
Publication Date: 2015-1-26
Last Updated on PCR: 2017-03-31 15:48:49